Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Modalis Therapeutics to participate in Nikkei Biotech Days conference
Notice regarding the Completion of the Pay-in Procedures for New Shares Issuance as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)
Financial Results for the Three Months Ended March 31, 2025
Consolidated Financial Results for the Three Months Ended March 31, 2025 [Japanese GAAP]
Modalis Therapeutics, Jan-Mar (1Q) Ordinary Profit Loss Widens
Notice regarding the Completion of the Pay-in Procedures for New Shares Issuance as post-delivery restricted-stock-based remuneration
Modalis to Present Preclinical Data on MDL-202 using CRISPR-GNDM epigenome editing technology at ASGCT 28th Annual Meeting
Modalis to Present MDL-202, a gene therapy for Myotonic Dystrophy Type 1 (DM1) using CRISPR-GNDM epigenome editing technology at 2025 MDF Conference
Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)